Neurosensory Risk After Semaglutide or Tirzepatide Is Lower Than Matched Antidiabetic and Bariatric Surgery Cohorts and Tracks Glycemic Burden
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for type 2 diabetes and obesity, but emerging evidence from randomized trials and real-world anecdotes suggest that neurosensory adverse events merit systematic investigation. We analyzed 670,422 initiators of semaglutide or tirzepatide across a large-scale federated EHR network and ascertained 14 new-onset neurosensory phenotypes over 12 months using AI-assisted clinical-note curation harmonized with ICD-10-CM codes. Among 128,377 at-risk GLP-1RA initiators — new users with at least two prescriptions within 12 months and complete 12-month follow-up, free of any studied phenotype at baseline — 29,519 (23.0%) had at least one newly documented phenotype, most commonly hypoesthesia/numbness in 16,143 patients (12.6%) and paresthesia in 15,415 patients (12.0%). Outcome ascertainment was validated by physician-led curation, with the review of 223 AI-identified events yielding a positive predictive value of 88.8% (95% CI, 84.0–92.3). In propensity-score–matched analyses, GLP-1RA initiators were associated with a 23% lower risk than initiators of the antidiabetic medications metformin, dipeptidyl-peptidase-4 (DPP-4) inhibitors, or sodium-glucose co-transporter-2 (SGLT2) inhibitors (19.7% versus 25.6%; RR, 0.77; 95% CI, 0.75–0.79; q12%, but showed no ordered association with achieved weight loss (P=0.867), baseline body-mass index (BMI, P=0.784) or BMI reduction (P=0.740). Maximum attained…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 16,143 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.